Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Status:
Terminated
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well tacrolimus, bortezomib, and anti-thymocyte globulin
(thymoglobulin) work in preventing low toxicity graft versus host disease (GVHD) in patients
with blood cancer who are undergoing donor stem cell transplant. Tacrolimus and
anti-thymocyte globulin may reduce the risk of the recipient's body rejecting the transplant
by suppressing the recipient's immune system. Giving bortezomib after the transplant may help
prevent GVHD by stopping the donor's cells from attacking the recipient. Giving tacrolimus,
bortezomib, and anti-thymocyte globulin may be a better way to prevent low toxicity GVHD in
patients with blood cancer undergoing donor stem cell transplant.